Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in Histopathology

Retrieve available abstracts of 88 articles:
HTML format



Single Articles


    March 2025
  1. CHAN R, Leung H, Li J, Poon I, et al
    Evaluation of breast-specific marker expression in metastatic breast cancers: Correlation with subtype switch.
    Histopathology. 2025;86:536-546.
    PubMed     Abstract available


  2. RAKHA EA, Quinn C
    Controversies regarding encapsulated papillary carcinoma of the breast: an approach to evaluation and categorisation.
    Histopathology. 2025;86:497-513.
    PubMed     Abstract available


    February 2025
  3. AI D, Arrey EN, Postlewait LM, Gao Y, et al
    The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response.
    Histopathology. 2025 Feb 4. doi: 10.1111/his.15417.
    PubMed     Abstract available


  4. YANG E, D'Alfonso TM, Morrow M, Brogi E, et al
    Discordance of human epidermal growth factor receptor 2-low status between breast primary and distant metastases with clinical-pathological correlation.
    Histopathology. 2025;86:441-449.
    PubMed     Abstract available


  5. TAHA SR, Boulos F
    E-cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes.
    Histopathology. 2025;86:327-340.
    PubMed     Abstract available


    January 2025
  6. ASHI A, Awaji AA, Bond J, Johnson CA, et al
    Threonine and tyrosine kinase (TTK) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting.
    Histopathology. 2025 Jan 7. doi: 10.1111/his.15399.
    PubMed     Abstract available


  7. LEE AHS, Hodi Z, Abbas A, Ellis IO, et al
    HER2-positive grade 1 invasive carcinomas of the breast.
    Histopathology. 2025;86:278-284.
    PubMed     Abstract available


    December 2024
  8. WANG Y, Liu L, Graff SL, Cheng L, et al
    Recent advancements in biomarkers and molecular diagnostics in hormonal receptor-positive breast cancer.
    Histopathology. 2024 Dec 17. doi: 10.1111/his.15395.
    PubMed     Abstract available


  9. ONAGI H, Horimoto Y, Okano S, Sasa K, et al
    Clinicopathological characteristics of Japanese patients with breast cancer and MET exon 14 skipping alterations.
    Histopathology. 2024 Dec 4. doi: 10.1111/his.15382.
    PubMed     Abstract available


  10. HEMPENIUS MA, Eenkhoorn MA, Hoeg H, Dabbs DJ, et al
    Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study.
    Histopathology. 2024;85:920-928.
    PubMed     Abstract available


    October 2024
  11. MATSUMOTO H, Miyata R, Tsuruta Y, Nakada N, et al
    Ki-67 evaluation using deep-learning model-assisted digital image analysis in breast cancer.
    Histopathology. 2024 Oct 31. doi: 10.1111/his.15356.
    PubMed     Abstract available


  12. WANG Y, Liu L, Graff SL, Cheng L, et al
    Locoregional event or dyssynchronous distant metastasis: clinicopathological and molecular analysis of contralateral axillary lymph node metastasis in breast cancer patients.
    Histopathology. 2024 Oct 22. doi: 10.1111/his.15345.
    PubMed     Abstract available


    September 2024
  13. WONG CJW, Md Nasir ND, Koh VCY, Campbell F, et al
    Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast.
    Histopathology. 2024;85:510-520.
    PubMed     Abstract available


  14. BATRA H, Bose PSC, Ding Y, Dai A, et al
    MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers.
    Histopathology. 2024;85:503-509.
    PubMed     Abstract available


  15. TURASHVILI G
    Nonneoplastic and neoplastic sclerosing lesions of the breast.
    Histopathology. 2024;85:383-396.
    PubMed     Abstract available


  16. GRABENSTETTER A, Brennan SB, Jochelson MS, Brogi E, et al
    Radial sclerosing lesions found on core needle biopsy: excision can be safely avoided.
    Histopathology. 2024;85:397-404.
    PubMed     Abstract available


  17. ELLIS I, Webster F, Allison KH, Dang C, et al
    Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;85:418-436.
    PubMed     Abstract available


    August 2024
  18. ZWAGER MC, Yu S, Buikema HJ, de Bock GH, et al
    Advancing Ki67 hotspot detection in breast cancer: a comparative analysis of automated digital image analysis algorithms.
    Histopathology. 2024 Aug 5. doi: 10.1111/his.15294.
    PubMed     Abstract available


    July 2024
  19. BANNIER PA, Broeckx G, Herpin L, Dubois R, et al
    Development of a deep-learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2-low cases.
    Histopathology. 2024 Jul 14. doi: 10.1111/his.15274.
    PubMed     Abstract available


  20. TOZBIKIAN G, Bui MM, Hicks DG, Jaffer S, et al
    Best practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists.
    Histopathology. 2024 Jul 8. doi: 10.1111/his.15275.
    PubMed     Abstract available


  21. ZHANG H, Finkelman BS, Ettel MG, Velez MJ, et al
    HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
    Histopathology. 2024;85:3-19.
    PubMed     Abstract available


    June 2024
  22. LASHEN AG, Toss M, Miligy I, Rewcastle E, et al
    Nottingham prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: a validation study.
    Histopathology. 2024 Jun 13. doi: 10.1111/his.15234.
    PubMed     Abstract available


  23. MILIGY IM, Awasthi R, Mir Y, Khurana A, et al
    Morphological and molecular changes of oestrogen receptor-positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study.
    Histopathology. 2024 Jun 7. doi: 10.1111/his.15238.
    PubMed     Abstract available


  24. LAOKULRATH N, Gudi M, Salahuddin SA, Chong APY, et al
    Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges.
    Histopathology. 2024 Jun 6. doi: 10.1111/his.15213.
    PubMed     Abstract available


  25. BOSSUYT V, Provenzano E, Symmans WF, Webster F, et al
    A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;84:1111-1129.
    PubMed     Abstract available


    May 2024
  26. LI J, Dong P, Wang X, Zhang J, et al
    Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
    Histopathology. 2024 May 15. doi: 10.1111/his.15205.
    PubMed     Abstract available


  27. HUANG CY, Chang RF, Lin CY, Hsieh MS, et al
    Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
    Histopathology. 2024;84:983-1002.
    PubMed     Abstract available


    April 2024
  28. BADR NM, Zaakouk M, Zhang Q, Kearns D, et al
    Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Histopathology. 2024 Apr 23. doi: 10.1111/his.15193.
    PubMed     Abstract available


  29. LI JJX, Ni SYB, Tsang JYS, Chan WY, et al
    Neutrophil-lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy.
    Histopathology. 2024;84:810-821.
    PubMed     Abstract available


  30. ALKHAYYAT R, Abbas A, Quinn CM, Rakha EA, et al
    Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
    Histopathology. 2024;84:723-741.
    PubMed     Abstract available


  31. AZAM AS, Tsang YW, Thirlwall J, Kimani PK, et al
    Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
    Histopathology. 2024;84:847-862.
    PubMed     Abstract available


    March 2024
  32. LY A, Garcia V, Blenman KRM, Ehinger A, et al
    Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research.
    Histopathology. 2024 Mar 3. doi: 10.1111/his.15140.
    PubMed     Abstract available


    January 2024
  33. LUI JW, Tsang JY, Li J, Ko CW, et al
    TRPS1 is a promising marker for all subtypes of breast cancer.
    Histopathology. 2024 Jan 3. doi: 10.1111/his.15126.
    PubMed     Abstract available


  34. SCHWARTZ CJ, Krings G, Chen YY
    Malignant phyllodes tumour with lymph node metastasis: a diagnostic conundrum resolved by next generation DNA sequencing.
    Histopathology. 2024;84:409-411.
    PubMed     Abstract available


    December 2023
  35. TAN PH, Mihir G, Laokulrath N, Rakha E, et al
    Practical approach to scoring HER2 immunohistochemistry in breast cancer in the wake of updated guidelines.
    Histopathology. 2023 Dec 12. doi: 10.1111/his.15117.
    PubMed    


  36. BOYRAZ B, Sgroi DC, Iafrate AJ, Lerwill MF, et al
    Atypical cystic hypersecretory lesions of the breast commonly harbour TP53 alterations.
    Histopathology. 2023;83:989-993.
    PubMed     Abstract available


    September 2023
  37. LEE AHS, Toss MS, James JJ, Hodi Z, et al
    Preoperative diagnosis of ductal carcinoma in situ of the breast over a 24-year period.
    Histopathology. 2023;83:435-442.
    PubMed     Abstract available


  38. RAKHA EA, Adebayo LA, Abbas A, Hodi Z, et al
    Second opinion (external specialist referral) practice of breast pathology: the Nottingham experience.
    Histopathology. 2023;83:394-405.
    PubMed     Abstract available


  39. GHANNAM SF, Rutland CS, Allegrucci C, Mongan NP, et al
    Encapsulated papillary carcinoma of the breast: does it have a native basement membrane?
    Histopathology. 2023;83:376-393.
    PubMed     Abstract available


  40. AIYER KTS, Kroon LJ, van Leenders GJLH
    Impact of comedonecrosis on prostate cancer outcome: a systematic review.
    Histopathology. 2023;83:339-347.
    PubMed     Abstract available


  41. JORNS JM, Farooq A, Puzyrenko A, Jarzembowski J, et al
    Giant juvenile fibroadenomas with and without prominent pseudoangiomatous stromal hyperplasia (PASH)-like change: clinicopathological and molecular characteristics.
    Histopathology. 2023;83:357-365.
    PubMed     Abstract available


    August 2023
  42. NIELSEN TO, Leung SCY, Riaz N, Mulligan AM, et al
    Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial.
    Histopathology. 2023 Aug 23. doi: 10.1111/his.15032.
    PubMed     Abstract available


  43. LEWIS G, Fong N, Gjeorgjievski SG, Li XB, et al
    Low-grade adenosquamous carcinoma of the breast: a clinical, morphological and immunohistochemical analysis of 25 patients.
    Histopathology. 2023;83:252-263.
    PubMed     Abstract available


    July 2023
  44. THORNE H, Devereux L, Li J, Alsop K, et al
    BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
    Histopathology. 2023;83:91-103.
    PubMed     Abstract available


    June 2023
  45. GOUGH M, Liu C, Srinivasan B, Wilkinson L, et al
    Improved concordance of challenging human epidermal growth factor receptor 2 dual in-situ hybridisation cases with the use of a digital image analysis algorithm in breast cancer.
    Histopathology. 2023 Jun 27. doi: 10.1111/his.15000.
    PubMed     Abstract available


    May 2023
  46. HARTER D, O'Connor SM, Hertel JD, Calhoun BC, et al
    Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy.
    Histopathology. 2023 May 31. doi: 10.1111/his.14966.
    PubMed     Abstract available


  47. LASHEN AG, Toss MS, Wootton L, Green AR, et al
    Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer.
    Histopathology. 2023 May 24. doi: 10.1111/his.14960.
    PubMed     Abstract available


    April 2023
  48. ZENG L, Koh VCY, Chen XY, Tan PH, et al
    Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathological parameters.
    Histopathology. 2023;82:779-788.
    PubMed     Abstract available


  49. LASHEN A, Toss MS, Fadhil W, Oni G, et al
    Evaluation oncotype DX((R)) 21-gene recurrence score and clinicopathological parameters: a single institutional experience.
    Histopathology. 2023;82:755-766.
    PubMed     Abstract available


  50. MD NASIR ND, Koh VCY, Cree IA, Ruiz BII, et al
    Phyllodes tumour evidence gaps mapped from the 5th edition of the WHO classification of tumours of the breast.
    Histopathology. 2023;82:704-712.
    PubMed     Abstract available


  51. CHARTIER S, Brochard C, Martinat C, Coussy F, et al
    TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas.
    Histopathology. 2023;82:664-671.
    PubMed     Abstract available


    February 2023
  52. IBRAHIM A, Toss MS, Atallah NM, Al Saleem M, et al
    Combined proliferation and apoptosis index provides better risk stratification in breast cancer.
    Histopathology. 2023 Feb 13. doi: 10.1111/his.14887.
    PubMed     Abstract available


  53. SODE M, Thagaard J, Eriksen JO, Laenkholm AV, et al
    Digital image analysis and assisted reading of the HER2 score display reduced concordance - Pitfalls in the categorization of HER2-low breast cancer.
    Histopathology. 2023 Feb 3. doi: 10.1111/his.14877.
    PubMed     Abstract available


  54. LAI BS, Tsang JY, Li JJ, Poon IK, et al
    Anatomical site and size of sentinel lymph node metastasis predicted additional axillary tumour burden and breast cancer survival.
    Histopathology. 2023 Feb 1. doi: 10.1111/his.14875.
    PubMed     Abstract available


    January 2023
  55. ELLIS IO, Rakha EA, Tse GM, Tan PH, et al
    An international unified approach to reporting and grading invasive breast cancer. An overview of the International Collaboration on Cancer Reporting (ICCR) initiative.
    Histopathology. 2023;82:189-197.
    PubMed     Abstract available


  56. RAKHA EA, Tse GM, Quinn CM
    An update on the pathological classification of breast cancer.
    Histopathology. 2023;82:5-16.
    PubMed     Abstract available


  57. CHAN RC, To CKC, Cheng KCT, Yoshikazu T, et al
    Artificial intelligence in breast cancer histopathology.
    Histopathology. 2023;82:198-210.
    PubMed     Abstract available


  58. PROVENZANO E, Shaaban AM
    Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer.
    Histopathology. 2023;82:170-188.
    PubMed     Abstract available


  59. SOKOLOVA A, Johnstone KJ, McCart Reed AE, Simpson PT, et al
    Hereditary breast cancer: syndromes, tumour pathology and molecular testing.
    Histopathology. 2023;82:70-82.
    PubMed     Abstract available


  60. NOURIEH M, Vibert R, Saint-Ghislain M, Cyrta J, et al
    Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction.
    Histopathology. 2023;82:162-169.
    PubMed     Abstract available


  61. TAN BY, Fox SB, Lakhani SR, Tan PH, et al
    Survey of recurrent diagnostic challenges in breast phyllodes tumours.
    Histopathology. 2023;82:95-105.
    PubMed     Abstract available


  62. TSANG JY, Tse GM
    Update on triple-negative breast cancers - highlighting subtyping update and treatment implication.
    Histopathology. 2023;82:17-35.
    PubMed     Abstract available


  63. LI JJX, Tse GM
    Marker assessments in ER-positive breast cancers: old markers, new applications?
    Histopathology. 2023;82:218-231.
    PubMed     Abstract available


    November 2022
  64. IBRAHIM A, Toss MS, Makhlouf S, Miligy IM, et al
    Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
    Histopathology. 2022 Nov 8. doi: 10.1111/his.14837.
    PubMed     Abstract available


  65. XU B, Viswanathan K, Umrau K, Al-Ameri TAD, et al
    Secretory carcinoma of the salivary gland: a multi-institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors.
    Histopathology. 2022;81:670-679.
    PubMed     Abstract available


    October 2022
  66. FOX SB, Webster F, Chen CJ, Chua B, et al
    Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2022;81:467-476.
    PubMed     Abstract available


    September 2022
  67. VERNEMMEN AIP, Li X, Roemen GMJM, Speel EM, et al
    Cutaneous metastases of internal malignancies: a single-institution experience.
    Histopathology. 2022;81:329-341.
    PubMed     Abstract available


    August 2022
  68. ATALLAH NM, Toss MS, Green AR, Mongan NP, et al
    Refining the definition of HER2 low class in invasive breast cancer.
    Histopathology. 2022 Aug 28. doi: 10.1111/his.14780.
    PubMed     Abstract available


  69. LASHEN A, Toss MS, Green AR, Mongan NP, et al
    Ki67 assessment in invasive luminal breast cancer: A comparative study between different scoring methods.
    Histopathology. 2022 Aug 23. doi: 10.1111/his.14781.
    PubMed     Abstract available


  70. OISHI N, Feldman AL
    CA9 expression in breast implant-associated anaplastic large cell lymphoma presenting in a lymph node.
    Histopathology. 2022;81:270-272.
    PubMed    


    July 2022
  71. KATAYAMA A, Starczynski J, Toss MS, Shaaban AM, et al
    The frequency and clinical significance of centromere enumeration probe 17 alterations in HER2 immunohistochemistry-equivocal invasive breast cancer.
    Histopathology. 2022 Jul 25. doi: 10.1111/his.14728.
    PubMed     Abstract available


  72. RAKHA E, Tan PH
    Head to head: do neuroendocrine tumours in the breast truly exist?
    Histopathology. 2022;81:2-14.
    PubMed     Abstract available


    February 2022
  73. KATAYAMA A, Toss MS, Parkin M, Sano T, et al
    Nuclear morphology in breast lesions: refining its assessment to improve diagnostic concordance.
    Histopathology. 2022;80:515-528.
    PubMed     Abstract available


  74. ABRAHAO-MACHADO LF, Bacchi CE, de Freitas CP, Hornick JL, et al
    Malignant peripheral nerve sheath tumour with multilineage divergent differentiation including a neuroblastic component.
    Histopathology. 2022;80:607-609.
    PubMed    


    January 2022
  75. KHOURY T, Quinn M, Tian W, Yan L, et al
    Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.
    Histopathology. 2022;80:291-303.
    PubMed     Abstract available


    December 2021
  76. LI J, Mi W, Guo Y, Ren X, et al
    Artificial intelligence for histological subtype classification of breast cancer: combining multi-scale feature maps and recurrent attention model.
    Histopathology. 2021 Dec 24. doi: 10.1111/his.14613.
    PubMed     Abstract available


  77. MA S, Zhao D, Liu Y, Rohr J, et al
    Some pleomorphic adenomas of the breast share PLAG1 rearrangements with the analogous tumour of the salivary glands.
    Histopathology. 2021;79:1030-1039.
    PubMed     Abstract available


    November 2021
  78. KLARIC KA, Riaz N, Asleh K, Wang XQ, et al
    SOX10 is a highly specific biomarker of basal-like breast cancer.
    Histopathology. 2021 Nov 1. doi: 10.1111/his.14592.
    PubMed     Abstract available


    October 2021
  79. RAKHA E, Mihai R, Abbas A, Bennett R, et al
    Diagnostic concordance of phyllodes tumour of the breast.
    Histopathology. 2021;79:607-618.
    PubMed     Abstract available


  80. CAI L, Yan K, Bu H, Yue M, et al
    Improving Ki67 assessment concordance by the use of an artificial intelligence-empowered microscope: a multi-institutional ring study.
    Histopathology. 2021;79:544-555.
    PubMed     Abstract available


  81. RAKHA E, Tan PH, Ellis I, Quinn C, et al
    Adenomyoepithelioma of the breast: a proposal for classification.
    Histopathology. 2021;79:465-479.
    PubMed     Abstract available


    August 2021
  82. MANSY M, Wotherspoon AC, El-Sharkawi D, Cunningham D, et al
    Fibrin-associated diffuse large B-cell lymphoma misdiagnosed as breast implant-associated anaplastic large-cell lymphoma.
    Histopathology. 2021;79:269-271.
    PubMed    


  83. BODEN ACS, Molin J, Garvin S, West RA, et al
    The human-in-the-loop: an evaluation of pathologists' interaction with artificial intelligence in clinical practice.
    Histopathology. 2021;79:210-218.
    PubMed     Abstract available


    May 2021
  84. MIHAI R, Callagy G, Qassid OL, Loughlin MO, et al
    Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast.
    Histopathology. 2021;78:871-881.
    PubMed     Abstract available


    April 2021
  85. RAKHA EA, Quinn CM, Foschini MP, Munoz Martin M, et al
    Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management.
    Histopathology. 2021;78:759-771.
    PubMed     Abstract available


    March 2021
  86. NOSKE A, Ammann JU, Wagner DC, Denkert C, et al
    A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
    Histopathology. 2021;78:567-577.
    PubMed     Abstract available


  87. GHOSSEIN CA, Khimraj A, Dogan S, Xu B, et al
    Metastasis to the thyroid gland: a single-institution 16-year experience.
    Histopathology. 2021;78:508-519.
    PubMed     Abstract available


  88. HODA RS, Bowman AS, Zehir A, Razavi P, et al
    Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 te
    Histopathology. 2021;78:498-507.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.